The notices it replaced
- Reissues: RFA-DA-14-008 FY14 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1)
- 2 steps back: RFA-DA-13-002 FY13 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1)
- 3 steps back: RFA-DA-12-011 FY12 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1)
- 4 steps back: RFA-DA-11-002 2011 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1)
- 5 steps back: RFA-DA-10-012 2010 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1)
- 6 steps back: RFA-DA-09-011 2009 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1)
- 7 steps back: RFA-DA-08-003
Replaced by RFA-DA-18-001.
Who won it before
13 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $10,256,651 in first-year total cost, median $792,500.
Most frequent study sections
- Special Emphasis Panel[ZDA1 GXM-A (04)]5
- Special Emphasis Panel[ZDA1 GXM-A (07)]4
- Special Emphasis Panel[ZDA1 HXO-H (10)]3
- Special Emphasis Panel[ZDA1 HXO-H (08)]1
Most frequent institutions
- BETH ISRAEL MEDICAL CTR (NEW YORK)1
- CASE WESTERN RESERVE UNIVERSITY1
- CINCINNATI CHILDRENS HOSP MED CTR1
- FRED HUTCHINSON CANCER RESEARCH CENTER1
- J. DAVID GLADSTONE INSTITUTES1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | A safety switch for an effective HIV-1 vaccine1DP1DA043912-01 | FARZAN, MICHAEL R. | SCRIPPS FLORIDA, FL | $960,000 | ZDA1 |
| 2017 | Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery1DP1DA043893-01 | KIM, PETER S | STANFORD UNIVERSITY, CA | $785,000 | ZDA1 |
| 2017 | Novel Approaches to Innate Immunity Against HIV-1 and Other Co-infection Viruses1DP1DA043915-01 | POESCHLA, ERIC M. | UNIVERSITY OF COLORADO DENVER, CO | $777,500 | ZDA1 |
| 2016 | Novel Proteomics Approach to HIV-Associated Neurocognitive Disorder & Drug Abuse1DP1DA041722-01 | LIPTON, STUART A | SCINTILLON INSTITUTE FOR PHOTOBIOLOGY, CA | $945,000 | ZDA1 |
| 2015 | Impact of Cannabis on Inflammation and Viral Persistence in Treated HIV/SIV1DP1DA037979-01 · under RFA-DA-14-008 | KLATT, NICHOLE ROSE | UNIVERSITY OF WASHINGTON, WA | $890,000 | ZDA1 |
| 2015 | TOWARDS A MORE RELEVANT MODEL OF HIV INFECTION1DP1DA039543-01 | OVERBAUGH, JULIE M. | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $880,000 | ZDA1 |
| 2015 | Repairing the intestinal epithelium from the dual action of HIV and drug use1DP1DA037997-01 · under RFA-DA-14-008 | LEVINE, ALAN DAVID | CASE WESTERN RESERVE UNIVERSITY, OH | $792,500 | ZDA1 |
| 2015 | Modeling HIV/AIDS Associated Neurological Disorders with Human Pluripotent Cells1DP1DA039562-01 | RANA, TARIQ M | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $775,000 | ZDA1 |
| 2015 | Reversing HIV T cell dysfunction by aptamer targeting of therapeutic siRNAs1DP1DA039560-01 | GILBOA, ELI | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $767,500 | ZDA1 |
| 2015 | Combined prevention to reduce initiation into injecting drug use1DP1DA039542-01 | DES JARLAIS, DON C | BETH ISRAEL MEDICAL CTR (NEW YORK), NY | $112,067 | ZDA1 |
| 2014 | A new model of accelerated immune aging in HIV-infected drug users1DP1DA038043-01 · under RFA-DA-14-008 | OTT, MELANIE MARIA | J. DAVID GLADSTONE INSTITUTES, CA | $955,000 | ZDA1 |
| 2014 | Mechanism of HIV Cell-Cell Transmission of Relevance to Substance Users1DP1DA038034-01 · under RFA-DA-14-008 | GOTTLINGER, HEINRICH | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $837,084 | ZDA1 |
| 2014 | A revolutionary vaccine approach to prevent HIV infection in substance abuse1DP1DA038017-01 · under RFA-DA-14-008 | WAGGONER, STEPHEN N. | CINCINNATI CHILDRENS HOSP MED CTR, OH | $780,000 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.